RE:RE:BioPubPandora wrote: MoneyTalks22 wrote: I zoomed in and felt very happy at the end of webcast that I had shares. They did explain again why they lost people to the enrollment because of qualifications for the trial and that some patients chose to leave the trial and AGN had to replace those numbers. IMO if those people that left the trial, perhaps they left the hospital because they could and were feeling better, or ran from the hospital, I would want to get as far away from death's door as possible, maybe the drug helped them, here's hoping. CEO also said that 150 enrollment would be reached by the time they came out with the data from the 75. - also AGN were now also looking at the use of Ifenprodil for cancers (liver and pancreatic). By the end of first week of December we'll know. p.s BioPub hosts were blown away with what AGN has accomplished so far being a smaller company. glta
Where might I find some written material that suggests they are looking at using Ifenprodil for prostate cancer. I have a friend who has prostate cancer and has found his first two chemo's have been failures and he is now starting on a third. He would be interested in seeing anything that sounds even a little bit positive.
I must apologize for going brain dead on this. MoneyTalks item talks about pancreatic cancer and my friend is battling pancreatic cancer and then my typing fingers together with dead brain type in the word prostate cancer - and that is not the first time. THey both start with 'P' but other than that I don't know why I confuse them. My thanks for the contributions regardless.